Stay updated with breaking news from Virtual Poster. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: ABIVAX / Key word(s): MiscellaneousABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATION AT UEG WEEK 2022 27.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax abstract on obefazimod phase 2b results selected for moderate...
Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance
EQS-News: ABIVAX / Key word(s): Miscellaneous ABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATI...
Berlin, Germany (PRWEB) July 30, 2022 -- Life Molecular Imaging (LMI) announces today that new research results on its approved and investigational positron
Session Dates: Friday, February 26 – Monday, March 1, 2021 Session Location: Virtual Poster Hall Poster No: L30 About ADMA Biologics, Inc. ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies a...